{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:09:50Z","timestamp":1776424190878,"version":"3.51.2"},"reference-count":33,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1136\/ejhpharm-2018-001823","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T17:15:52Z","timestamp":1553015752000},"page":"194-201","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review"],"prefix":"10.1136","volume":"27","author":[{"given":"H\u00e9ctor","family":"Crist\u00f3bal Guti\u00e9rrez","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Universitario Marques de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Lara","family":"Pelayo-Negro","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario Marques de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"G\u00f3mez G\u00f3mez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario Marques de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Mart\u00edn Vega","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario Marques de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Valero Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario Marques de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"2025090701184824000_27.4.194.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023144"},{"key":"2025090701184824000_27.4.194.2","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12153"},{"key":"2025090701184824000_27.4.194.3","doi-asserted-by":"crossref","unstructured":"Ando Y , Coelho T , Berk JL , et al . Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8.doi:10.1186\/1750-1172-8-31","DOI":"10.1186\/1750-1172-8-31"},{"key":"2025090701184824000_27.4.194.4","unstructured":"Adams P . Polineuropat\u00eda amiloide familiar. Orphanet, 2017. Available: http:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=ES&Expert=85447"},{"key":"2025090701184824000_27.4.194.5","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000288"},{"key":"2025090701184824000_27.4.194.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001870"},{"key":"2025090701184824000_27.4.194.7","unstructured":"Adams P . Current opinion 2016: first European consensus for diagnosis, management and treatment of ATTR."},{"key":"2025090701184824000_27.4.194.8","doi-asserted-by":"crossref","unstructured":"Hutton B . La extensi\u00f3n de la declaraci\u00f3n PRISMA para revisiones sistem\u00e1ticas que incorporan metaan\u00e1lisis en Red: PRISMA-NMA. Med Clin 2016.","DOI":"10.1016\/j.medcli.2016.02.025"},{"key":"2025090701184824000_27.4.194.9","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"2025090701184824000_27.4.194.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"2025090701184824000_27.4.194.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7051-7"},{"key":"2025090701184824000_27.4.194.12","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1207163"},{"key":"2025090701184824000_27.4.194.13","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1301419"},{"key":"2025090701184824000_27.4.194.14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12225"},{"key":"2025090701184824000_27.4.194.15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2016.01.046","article-title":"Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study","volume":"362","author":"Ando","year":"2016","journal-title":"J Neurol Sci"},{"key":"2025090701184824000_27.4.194.16","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-013-9512-x"},{"key":"2025090701184824000_27.4.194.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890"},{"key":"2025090701184824000_27.4.194.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"2025090701184824000_27.4.194.19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bcp.12561","article-title":"The effect of tafamidis on the QTc interval in healthy subjects","volume":"79","author":"Klamerus","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2025090701184824000_27.4.194.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8337-3"},{"key":"2025090701184824000_27.4.194.21","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J Neurol"},{"key":"2025090701184824000_27.4.194.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.283815"},{"key":"2025090701184824000_27.4.194.23","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2014.997872"},{"key":"2025090701184824000_27.4.194.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2012.00303.x"},{"issue":"Suppl 1","key":"2025090701184824000_27.4.194.25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/13506129.2012.678509","article-title":"The diflunisal trial: study accrual and drug tolerance. Familial Amyloidosis Consortium","volume":"19","author":"Berk","year":"2012","journal-title":"Amyloid"},{"key":"2025090701184824000_27.4.194.26","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000574"},{"key":"2025090701184824000_27.4.194.27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/13506129.2015.1123149","article-title":"Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation","volume":"23","author":"Okumura","year":"2016","journal-title":"Amyloid"},{"key":"2025090701184824000_27.4.194.28","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.2147\/DDDT.S96893","article-title":"Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study","volume":"9","author":"aus dem Siepen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2025090701184824000_27.4.194.29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/00365510151067884","article-title":"Scavenger treatment of free radical injury in familial amyloidotic polyneuropathy: a study on Swedish transplanted and non-transplanted patients","volume":"61","author":"Suhr","year":"2001","journal-title":"Scand J Clin Lab Invest"},{"key":"2025090701184824000_27.4.194.30","doi-asserted-by":"crossref","unstructured":"Suhr OB , Coelho T , Buades J , et al . Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 2015;10.doi:10.1186\/s13023-015-0326-6","DOI":"10.1186\/s13023-015-0326-6"},{"key":"2025090701184824000_27.4.194.31","doi-asserted-by":"crossref","unstructured":"Adams D , Suhr OB , Dyck PJ , et al . Trial design and rationale for Apollo, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 2017;17.doi:10.1186\/s12883-017-0948-5","DOI":"10.1186\/s12883-017-0948-5"},{"key":"2025090701184824000_27.4.194.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"2025090701184824000_27.4.194.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2018-001823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:18:59Z","timestamp":1757233139000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2018-001823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,6,25]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/ejhpharm-2018-001823"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2018-001823","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]}}}